Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab vs Rituximab in Indolent NHL
NCT01889797Phase 2Terminated
- Sponsor
- PrECOG
- Start
- Dec 2013
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by PrECOG. Started Dec 2013; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT01889797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889797.